Patients with cancer demonstrate particularly poor outcomes from COVID-19
. Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, has published results from a study that analyzed a cohort of 38,628 cancer patients to gain insight into why cancer patients have poor outcomes from COVID-19. Investigators identified that ACE2, TMPRSS2, and other proteases that are key factors necessary for viral attachment to and entry into target cells.
Caris study results have been published in
Scientific Reports, A Nature Research Journal, finding substantial variability of expression of ACE2 and TMPRSS2 across tumor types while identifying subpopulations expressing ACE2 at very high levels. This study provides the first systematic assessment of RNA expression of key molecules involved in the infectious process, and offers a biological explanation for why cancer patients do poorly when afflicted wi
UMCG: Afschaffing routinematig vinken levert 24 minuten op voor patiënten
groningen.nieuws.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from groningen.nieuws.nl Daily Mail and Mail on Sunday newspapers.
ZIRE: Meer kwaliteit met minder registraties
skipr.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from skipr.nl Daily Mail and Mail on Sunday newspapers.
Caris Life Sciences Accurately Identifies 21 Cancer Types Using Artificial Intelligence Derived Molecular Signatures
New Data Published in Translational Oncology
News provided by
Share this article
Share this article
IRVING, Texas, Jan. 19, 2021 /PRNewswire/ Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, today announced positive results from a study using MI GPSai™ (Genomic Prevalence Score) an artificial intelligence driven product using DNA sequencing and whole transcriptome data to aid in the diagnosis of cancer.
Caris MI GPSai algorithm trained on genomic data from over 34,000 cases and genomic and transcriptomic data from more than 23,000 cases and was validated on over 19,500 cases. MI GPSai predicted the tumor type in the labeled data set with an accuracy of over 94% on 93% of cases while deliberating amongst 21 possible categories of cancer. When also considering